Pitobrutinib adverse reactions

Pirtobrutinib, trade name Jaypirca, is a kinase inhibitor produced by Lilly of the United States. The drug is primarily indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two systemic therapies, including BTK inhibitors. Pitobrutinib exerts its therapeutic effect by inhibiting specific tyrosine kinases in lymphoma cells, thereby blocking the proliferation and survival of malignant lymphoma cells.

Although pitobrutinib has shown good efficacy in the treatment of lymphoma, patients still need to pay attention to possible adverse reactions during use. The most common adverse reactions (≥15%) include fatigue, musculoskeletal pain, diarrhea, edema, dyspnea, pneumonia, and bruising. Additionally, some patients may experience digestive symptoms such as nausea, vomiting, and stomach upset, as well as skin reactions such as rash, itching, dryness, or scaling.

It is worth noting that Pitobrutinib may have certain effects on the blood system, leading to thrombocytopenia, anemia, or leukopenia. These side effects generally appear within the first few months of treatment but are usually reversible. Patients should have regular blood tests so that any abnormalities can be detected and dealt with promptly.

In addition to the common side effects mentioned above, pitobrutinib may also cause other serious adverse reactions. For example, patients at risk for serious bleeding should use this drug with caution because the drug may cause bleeding events. At the same time, patients with cardiovascular diseases such as arrhythmia, heart disease, or hypertension should also use it with caution because the drug may cause heart-related adverse reactions. In addition, patients receiving pitobrutinib may develop Grade 3 or 4 laboratory abnormalities, such as decreased neutrophil count, decreased lymphocyte count, and decreased platelet count.

During the period of treatment with Pitobrutinib, patients should pay close attention to their physical condition and report any discomfort or side effects to their doctors in a timely manner. In particular, if you have unusual bruising, prolonged bleeding, or blood in your stool or urine, you should seek medical attention immediately. Anaphylaxis, although rare, has been reported and symptoms may include rash, itching, swelling, severe dizziness and difficulty breathing. If an allergic reaction occurs, immediate medical attention is required.

To sum up, Pitobrutinib is of great significance in the treatment of lymphoma, but patients must strictly follow the doctor's instructions and pay close attention to the body's reaction during use to ensure the safety and effectiveness of the treatment.

At present, Pitobrutinib has not yet appeared in the domestic market. For domestic patients who urgently need this drug, they can only choose to go overseas to purchase it or obtain purchase consultation through regular overseas medical consulting companies. It is understood that there are differences between the original drug and generic drugs of Pitobrutinib in overseas markets. Taking the original drug marketed in the United States as an example, the price of 50mg*30 tablets is as high as about 100,000 yuan. In comparison, the price of generic drugs in Laos is much more affordable, only about 4,500 yuan. If you want to learn more about pitobrutinib, please be sure to consult a regular overseas medical consulting company.

xa0

Reference: https://synapse.patsnap.com/article/what-are-the-side-effects-of-pirtobrutinib